Dear Editor,
Dermatologists are facing unprecedented challenges due to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in caring for their patients. Treatment algorithms utilized prior to the coronavirus disease 2019 (COVID‐19) pandemic are no longer applicable. 1 Nail lichen planus (NLP) is a true nail emergency, sometimes with an aggressive course, resulting in scarring, permanent nail loss, and significant impact on daily activities. 2 Treatment of NLP is difficult, and topicals are generally not preferred due to poor nail plate penetration and compliance. 3 Thus, intralesional and systemic therapies are mainstays of NLP treatment. Immunosuppressants play key roles in NLP treatment; however, their use may be a COVID‐19‐related mortality risk factor. 4 Therefore, we analyzed adverse event data in NLP patients receiving intralesional or systemic therapies and provided therapeutic recommendations.
Data on the adverse events upon treatment of NLP are displayed in Table 1. There were no reported infections in any of the studies. Triamcinolone acetonide (TAC) is considered first‐line treatment for NLP. 3 The intralesional route is recommended in the absence of nail bed disease. 3 Intramuscular TAC is considered as an adjunct to intralesional administration for severe disease, particularly if >3 nails are affected; for nail bed lichen planus features, 17 intramuscular administration is favored. 3 Intralesional administration‐related side effects are mild, including nail plate atrophy, subungual hematoma, and transient digit numbness 3 ; the risk of systemic toxicity is negligible. Although intramuscular TAC and prednisone‐related infections have not been reported in NLP patients (Table 1), studies are small and because they are both immunosuppressants, there are at least theoretically increased infection risks. Since intralesional/intramuscular TAC administration requires an in‐person visit, these injections should be discontinued during the pandemic. Superpotent topical steroids under occlusion or oral non‐immunosuppressants are preferred. An in‐office visit for intralesional/intramuscular injections can be considered on a case‐by‐case basis if NLP is progressive despite the use of alternative topical or systemic treatments.
TABLE 1.
Studies on nail lichen planus treatments with rates of adverse events/infections
| Reference | Study type | Medication (route of administration): dosage (number of patients) | Adverse event (n, %) | Any infection (n, %) |
|---|---|---|---|---|
| 5 | Case report | Alitretinoin (oral): 30 mg daily (N = 1) | None reported | None reported |
| 6 | Case series | Alitretinoin (oral): 30 mg/day for 3 months and 10 mg/day for 3 months (N = 3) | Mild skin dryness (unknown) | None reported |
| 7 | Case report | Alitretinoin (oral): 30 mg daily (N = 2) | Headache (N = 1, 50%), elevated liver enzymes (N = 1, 50%), diverticulitis (N = 1, 50%) | None reported |
| 8 | Case report | Etretinate (oral): 30 mg daily for 1 month, then 20 mg daily for 8 months, and then gradually reduced until discontinuation (N = 1) | None reported | None reported |
| 9 | Retrospective study | Prednisone (oral): 0.5 mg/kg (N = 15) | None reported | None reported |
| Triamcinolone acetonide (intramuscular): 0.5 mg/kg per month (N = 2) | None reported | None reported | ||
| Triamcinolone acetonide (intralesional): 5 mg/mL every 4 weeks (N = 4) | None reported | None reported | ||
| 10 | Prospective study | Triamcinolone acetonide (intralesional): 5 mg/mL monthly for 6 months (N = 12) | Unknown | Unknown |
| 11 | Retrospective study | Triamcinolone acetonide (intramuscular): 0.5‐1 mg/kg per month (N = 10) | Lipoatrophy at site of injection (N = 2, 20%), cushinoid facies (N = 1, 10%) | None reported |
| 12 | Case report | Triamcinolone acetonide (intralesional): 10 mg/mL (N = 1) | None reported | None reported |
| 13 | Retrospective study | Triamcinolone acetonide (intralesional): 10 mg/mL monthly (N = 8) | Transient subungual hemorrhages (N = 2, 25%) | None reported |
| Triamcinolone acetonide (intramuscular): 0.5 mg/kg monthly (N = 67) | None reported | None reported | ||
| 14 | Prospective study | Triamcinolone acetonide (intradermal with needleless injector): 5 mg/mL monthly (N = 11) | Slight, transient atrophy (unknown) | None reported |
| 15 | Case report | Chloroquine phosphate (oral): 250 mg twice daily for 30 weeks and then 250 mg once daily for 4 weeks (N = 1) | None reported | None reported |
| 16 | Case report | Cyclosporine (oral): 3 mg/kg (100 mg twice a day) (N = 1) | Hypertension (N = 1, 100%) | None reported |
Retinoids are considered second‐line treatment for NLP. 3 They do not suppress the immune system to the same extent as systemic corticosteroids; no retinoid‐related NLP infections have been reported. Notably, retinoids have been shown to inhibit replication of various viruses (human herpesvirus 8, human immunodeficiency virus type 1, herpes‐simplex virus type 1, measles virus, mumps virus, polyoma virus, hepatitis B virus, and hepatitis C virus) in vitro; however, their effect on SARS‐CoV‐2 is unknown.
Azathioprine, cyclosporine, and mycophenolate mofetil are third‐line NLP treatments. 3 They are known to cause immunosuppression. However, their effect on susceptibility to and increased severity of COVID‐19 infection is largely unknown. Treating physicians may consider tapering to the lowest effective dose during the pandemic. For patients positive/symptomatic for COVID‐19, these immunosuppressants should be discontinued. Of note, cyclosporine has been shown to have anticoronavirus activity. 18
There is a case report of NLP treatment with chloroquine phosphate, with improvement noted after 10 weeks, and complete remission (20 nails) after 30 weeks. 15 There were no adverse events. Chloroquine and hydroxychloroquine have been shown to inhibit SARS‐CoV‐2 in vitro, with the latter showing higher efficacy and less toxicity. 19 However, their efficacy for COVID‐19 treatment remains an area of active investigation. Completed trials have shown mixed results and varying degrees of bias with poor study design. 20
NLP is a true nail emergency and may lead to permanent debilitating nail loss. Thus, treatment must be aggressive and individualized. Careful pharmacologic selection is mandatory during this pandemic, and collection of specific COVID‐19 data is warranted to establish evidence‐based guidelines.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
- 1. Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID‐19 pandemic. Submitted. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Lipner SR. Nail lichen planus: a true nail emergency. J Am Acad Dermatol. 2019;80(6):e177‐e178. [DOI] [PubMed] [Google Scholar]
- 3. Iorizzo M, Tosti A, Starace M, et al. Isolated nail lichen planus: an expert consensus on treatment of the classical form. J Am Acad Dermatol. 2020. 10.1016/j.jaad.2020.02.056. [DOI] [PubMed] [Google Scholar]
- 4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Pinter A, Pätzold S, Kaufmann R. Lichen planus of nails—successful treatment with alitretinoin. J Dtsch Dermatol Ges. 2011;9(12):1033‐1034. 10.1111/j.1610-0387.2011.07773.x. [DOI] [PubMed] [Google Scholar]
- 6. Iorizzo M. Nail lichen planus—a possible new indication for oral alitretinoin. J Eur Acad Dermatol Venereol. 2016;30(3):509‐510. 10.1111/jdv.12904. [DOI] [PubMed] [Google Scholar]
- 7. Alsenaid A, Eder I, Ruzicka T, Braun‐Falco M, Wolf R. Successful treatment of nail lichen planus with alitretinoin: report of 2 cases and review of the literature. Dermatology. 2014;229(4):293‐296. 10.1159/000365655. [DOI] [PubMed] [Google Scholar]
- 8. Kato N, Ueno H. Isolated lichen planus of the nails treated with etretinate. J Dermatol. 1993;20(9):577‐580. 10.1111/j.1346-8138.1993.tb01342.x. [DOI] [PubMed] [Google Scholar]
- 9. Tosti A, Peluso AM, Fanti PA, Piraccini BM. Nail lichen planus: clinical and pathologic study of twenty‐four patients. J Am Acad Dermatol. 1993;28(5 Pt 1):724‐730. 10.1016/0190-9622(93)70100-8. [DOI] [PubMed] [Google Scholar]
- 10. Grover C, Bansal S, Nanda S, Reddy BS. Efficacy of triamcinolone acetonide in various acquired nail dystrophies. J Dermatol. 2005;32(12):963‐968. 10.1111/j.1346-8138.2005.tb00882.x. [DOI] [PubMed] [Google Scholar]
- 11. Tosti A, Piraccini BM, Cambiaghi S, Jorizzo M. Nail lichen planus in children: clinical features, response to treatment, and long‐term follow‐up. Arch Dermatol. 2001;137(8):1027‐1032. [PubMed] [Google Scholar]
- 12. Brauns B, Stahl M, Schön MP, Zutt M. Intralesional steroid injection alleviates nail lichen planus. Int J Dermatol. 2011;50(5):626‐627. 10.1111/j.1365-4632.2010.04786.x. [DOI] [PubMed] [Google Scholar]
- 13. Piraccini BM, Saccani E, Starace M, Balestri R, Tosti A. Nail lichen planus: response to treatment and long term follow‐up. Eur J Dermatol. 2010;20(4):489‐496. 10.1684/ejd.2010.0952. [DOI] [PubMed] [Google Scholar]
- 14. Abell E, Samman PD. Intradermal triamcinolone treatment of nail dystrophies. Br J Dermatol. 1973;89(2):191‐197. 10.1111/j.1365-2133.1973.tb02956.x. [DOI] [PubMed] [Google Scholar]
- 15. Mostafa WZ. Lichen planus of the nail: treatment with antimalarials. J Am Acad Dermatol. 1989;20(2 Pt 1):289‐290. 10.1016/s0190-9622(89)80060-x. [DOI] [PubMed] [Google Scholar]
- 16. Florian B, Angelika J, Ernst SR. Successful treatment of palmoplantar nail lichen planus with cyclosporine. J Dtsch Dermatol Ges. 2014;12(8):724‐725. 10.1111/ddg.12325. [DOI] [PubMed] [Google Scholar]
- 17. McClanahan DR, English JC 3rd. Therapeutics for adult nail psoriasis and nail lichen planus: a guide for clinicians. Am J Clin Dermatol. 2018;19(4):559‐584. [DOI] [PubMed] [Google Scholar]
- 18. Pfefferle S, Schopf J, Kogl M, et al. The SARS‐coronavirus‐host interactome: identification of cyclophilins as target for pan‐coronavirus inhibitors. PLoS Pathog. 2011;7(10):e1002331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS‐CoV‐2 infection in vitro. Cell Discov. 2020;6:16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Chowdhury MS, Rathod J, Gernsheimer J. A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID‐19. Acad Emerg Med. 2020. 10.1111/acem.14005. [DOI] [PMC free article] [PubMed] [Google Scholar]